seed
Stage
1
Investors
About
CC Diagnostics develops a PCR-based reagent kit using novel epigenetic biomarkers for early and more sensitive detection of cervical cancer, aiming to improve diagnostic accuracy and reduce delays compared to traditional screening methods.
Explore CC Diagnostics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.